JAK2 and myeloproliferative neoplasm: Moreover, primary cells from MPN patients treated with the same combination showed a lower colony-forming capacity compared with primary cells treated with ruxolitinib only, suggesting that PIM inhibitors together with JAK2 inhibitors could represent a valid therapeutic option [152].